MICROVIABLE THERAPEUTICS
Mission & Vision
Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
Microviable’s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients’ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.
NEWS
You can follow the latest news of MicroViable in this section
Microviable will be presenting at Farmaforum 2023
Microviable Therapeutics will be presenting at Farmaforum 2023 taking place on September 20th-21th at Madrid. [...]
Pilar Manrique, Research Scientist at Microviable Therapeuthics, talks about the donor-based microbiome therapeutic products research and development.
During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiome Post sat [...]
Microviable Therapeutics seeks more than five million to secure a clinical trial
Microviable Therapeutics, which develops oral drugs based on microbiota-derived products, hopes to soon open a [...]
CONTACT

Get in touch with us for any questions using the following contact form.